The Burrill Personalized Medicine Meeting
Featured SpeakersKeyan Salari
Massachusetts General Hospital
Keyan Salari is currently completing his residency in the Harvard Program in Urologic Surgery at the Massachusetts General Hospital.
Keyan graduated in 2012 from the Medical Scientist Training Program at Stanford University School of Medicine, where he earned an MD and PhD in Genetics. He received the Arnold P. Gold Humanism in Medicine Award for his clinical skills and dedication to patient care. His PhD thesis focused on characterizing cancer genomes using high-throughput DNA microarray and sequencing technologies. His work has led to novel findings in the biology of prostate, colorectal, breast, and lung cancers, and has resulted in over 20 scientific publications in leading journals, including PNAS, Nature Genetics, PLoS Medicine, and PLoS Genetics. Keyan is a 2004 graduate of the University of California at Berkeley, where he earned a BA with high distinction and honors in Molecular and Cell Biology. He was elected to Phi Beta Kappa, was a Howard Hughes Medical Institute Biology Fellow, and was awarded Berkeley’s Spencer W. Brown Award for best undergraduate research in Genetics.
In 2010, Keyan spearheaded the development of a novel course on personalized medicine at Stanford, where students have the opportunity to undergo personal genome testing as part of the course curriculum. With students exploring their own genome data in the classroom to learn how genetics impacts clinical medicine, Keyan’s controversial course drew national attention and was featured in Nature, Scientific American, USA Today and the San Francisco Chronicle. He recently published the first study demonstrating that personal genome testing can enhance student learning in the classroom.
InnoThink Center for Research in Biomedical Innovation
Bernard Munos is the founder of InnoThink, a consultancy that focuses on pharmaceutical innovation—specifically, where it comes from and how to get more of it. He was previously an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D.
In research published in Nature and Science Translational Medicine and profiled by Forbes, Munos has argued for refocusing drug R&D on risk-taking and breakthrough science, and for eliminating the knowledge gaps that are hindering the development of personalized medicine.
Munos is a member of the Advisory Council and of the Cures Acceleration Network Review Board of NIH’s National Center for Advancing Translational Sciences (NCATS), a member of the Institute of Medicine’s Forum on Drug R&D and Translation, a Senior Fellow at FasterCures (a Center of the Milken Institute), and a member of the Advisory Board of Science Translational Medicine. He is also a non-executive director of Glenmark Pharmaceuticals, and serves as an advisor to or board member of a dozen other companies and publicly-financed research organizations.. The popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He blogs about pharmaceutical innovation on the Forbes and FasterCures websites.
Munos received his M.B.A. from Stanford University, and holds graduate degrees in economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences.
Chairman & CEO
Strand Life Sciences
Vijay Chandru (PhD, MIT ‘82) is an academic turned entrepreneur. His academic career in computational mathematics spanned over two decades as a professor at Purdue University and Indian Institute of Science, with visiting appointments at IBM, UPenn, Stanford and MIT. He is a fellow of the national academies of science and engineering in India. Vijay was inducted as a Technology Pioneer by the World Economic Forum in Davos in 2006.
As an entrepreneur, Vijay leads the translational biology company Strand Life Sciences. Since 2007, Strand has been a global leader in bioinformatics with its analytic tools licensed to over 2000 research biologists worldwide. With around 180 high calibre scientists engaged in informatics, curation and lab operations, Strand is now leading the charge in clinical genomics and personalized medicine with several hospital chains in India. Strand’s validated, end-to-end sequence alignment to clinical reporting informatics platform will address the global market opportunity.
President, Chief Executive Officer and Chairman
Clifford A. Reid, Ph.D., is Complete Genomics’ co-founder and has served as the company’s President, Chief Executive Officer and Chairman since July 2005 and as a member of its board of directors since July 2005. From March 2003 to September 2005, Dr. Reid was Vice President of Collaborative Solutions at Open Text Corporation, a software company. In 1995, Dr. Reid co-founded Eloquent, Inc., a digital video communications company, and served as its Chief Executive Officer until 1999 and as its Chairman until 2003, when it was acquired by Open Text. In 1988, Dr. Reid co-founded Verity, Inc., an enterprise text search engine company, and served as its Vice President of Engineering from 1988 to 1992 and as its Executive Vice President from 1992 to 1993. Dr. Reid received a B.S. in Physics from the Massachusetts Institute of Technology, an M.B.A. from Harvard University and a Ph.D. in Management Science and Engineering from Stanford University.
CEO & Co-Founder
Colin Hill is a frequent speaker at international scientific and industry conferences and serves as co-chair of O’Reilly Media’s Strata Rx healthcare Big Data conference. He has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist, and is the author of the “Healthcare 2020” blog on Forbes.com. He serves as Chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease, on the advisory board of the Boston Medical Center’s philanthropic trust, and as the chair of the industrial advisory board of EBICS.
In 2004, Colin was named to MIT Technology Review’s TR35 list of the top innovators in the world under the age of 35. He graduated from Virginia Tech with a degree in physics and earned master’s degrees in physics from McGill University and Cornell University.
Jessica Richman started and sold her first company after high school. At Stanford University she earned degrees in Economics and Science, Technology and Society (with a computer science focus). Along the way, she worked for Google, McKinsey, Lehman Brothers, the Grameen Bank, and top-tier Silicon Valley venture firms. Jessica arrived at Oxford University as a Clarendon Scholar and completed an MSc at the Oxford Internet Institute. She is currently a DPhil student at Oxford with a focus on innovation, social networks, and collective intelligence.
Jessica is a co-founder of uBiome, the world’s largest crowdfunded citizen science startup. uBiome has been featured in Wired, MIT Technology Review, Scientific American, NPR, FoxNews, ABC News, and dozens of other media outlets. She has spoken at TEDMED, SciFoo, Oxford University, and many other conferences and universities.
Professor and Chair, Neurology
University of California, San Francisco School of Medicine
Stephen L. Hauser, M.D. is the Robert A. Fishman Distinguished Professor and Chair of the Department of Neurology at UCSF. He is a graduate of MIT (Phi Beta Kappa) and Harvard Medical School (Magna Cum Laude). He trained in internal medicine at the New York Hospital–Cornell Medical Center, in neurology at the Massachusetts General Hospital (MGH), and in immunology at Harvard Medical School and the Institute Pasteur in Paris, France, and was a faculty member at Harvard Medical School before moving to UCSF.
A neuroimmunologist, Dr. Hauser’s research has advanced our understanding of the genetic basis, immune mechanisms, and treatment of multiple sclerosis. Dr. Hauser is a fellow of the American Academy of Arts and Sciences and the American Academy of Physicians, a member of the Institute of Medicine of the National Academy of Sciences (former Chair of Committee on Gulf War and Health Outcomes and current Chair of Committee on Long Term Effects of Blast Exposure), and editor-in-chief of Annals of Neurology. In April 2010 Dr. Hauser was appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues charged with advising the President on issues that may emerge from advances in biomedicine and related areas of science and technology.
Foley & Lardner LLP
Richard Kaufman is a partner with Foley & Lardner LLP and vice chair of the firm’s Private Equity & Venture Capital Practice and co-chair of the Life Sciences Industry Team. He is also a member of the Transactional & Securities Practice.
Mr. Kaufman has significant experience with a wide variety of corporate and securities transactions for companies in the life sciences industry, including developers of drugs, biologics, medical devices, and discovery and informatics tools. His practice includes structuring and negotiation of strategic partnerships and collaborations, technology transfers and licenses, spin-out transactions, manufacturing agreements, and clinical research agreements, as well as engagements for financings, mergers, acquisitions, and divestitures.
Co-founder and CEO
Ari Tulla is a Co-founder and CEO of BetterDoctor. BetterDoctor’s web and mobile apps help patients find the best doctor and dentist who accepts their insurance plan. BetterDoctor’s mission is to simplify healthcare and make doctor search more transparent.
Prior to BetterDoctor, Ari lead Nokia’s game and application businesses where he was responsible for creation of thousands of mobile apps with over 100M downloads. Ari has over a decade of experience on creating new delightful consumer products and experiences.
Neil K. Warma
President and Chief Executive Officer
Neil K. Warma was appointed President and Chief Executive Officer of Opexa Therapeutics, Inc. in June 2008. He has more than 20 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, Mr. Warma served as President & CEO and a member of the Board of Directors of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company developing a novel class of protein therapeutics. While at Viron, Mr. Warma positioned the company as a leader in the treatment of serious inflammatory disorders.
Prior to joining Viron, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies, which was ultimately sold to a large public European firm. Prior to MedExact, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in international policy and advocacy and in global marketing.
Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Business at York University in Toronto. He currently serves on the Board of Directors of BioHouston, Inc.
CEO and co-founder
Adina Mangubat is the CEO and co-founder of rapidly growing Spiral Genetics, a Seattle-based bioinformatics company. Spiral Genetics makes big data software for analyzing DNA in medical and agricultural research. In her current role, Adina was featured in Forbes 2012 30 under 30 for Science and Healthcare and was a keynote panelist at the 2013 BIO conference in Chicago.
Prior to starting Spiral Genetics, she worked with two other high technology start-up companies in smart grid and home automation technology. As a passionate mentor for young innovators, Adina co-founded DragonCurve which is an organization dedicated to supporting young entrepreneurship. Adina holds a B.S. in Psychology with a focus on Biopsychology, Psychopharmacology and Entrepreneurship from the University of Washington.
American Academy of Microbiology
Ann Reid is Director of the American Academy of Microbiology, the honorific branch of the American Society of Microbiology. As Director of the Academy’s colloquium program, she has organized interdisciplinary colloquia on many critical issues in microbiology, including: How Microbes Can Help Feed the World, Bringing the Lab to the Patient: Developing Point of Care Diagnostics for Resource-Limited Settings, and Moving Targets: Fighting the Evolution of Resistance in Infections, Pests, and Cancer.
In 2010, she spearheaded the development of a new kind of colloquium to provide scientifically sound answers to questions the public might have about microbiology topics. The new series, called FAQs, includes reports on Adult Vaccination, E. coli, West Nile Virus, and others. A report on a FAQ colloquium on the Human Microbiome that took place in July 2013 is in preparation.
Before directing the AAM, Reid was a senior program officer on the Board of Life Sciences of the National Research Council (NRC), an arm of the National Academy of Science. During her tenure, she worked on over a dozen major projects, including a seminal report on the then emerging science of metagenomics, as well as workshops on novel approaches to developing antimicrobial therapeutics and the prospects for developing an anti-polio antiviral therapeutic. The metagenomics report was an early influence on the NIH’s decision-making process during the development of the Human Microbiome Project. She also directed two of BLS’s most ambitious recent projects, “The Role of Theory in 21st Century Biology” and “A New Biology for the 21st Century.”
Prior to her time at the National Academies, Reid was a molecular biologist at the Armed Forces Institute of Pathology, where she developed a number of techniques for applying molecular biology techniques to formalin-fixed, paraffin-embedded tissue samples. She was one of the leaders of the team that deciphered the sequence of the 1918 influenza virus.
Adult Genetics Service at Baylor College of Medicine
Shweta Dhar, MD, MS, FACMG is a board certified Internist and Clinical Geneticist and is the Medical Director for the Adult Genetics Service at Baylor College of Medicine (BCM) in Houston, Texas. She sees adult patients with known or suspected genetic conditions at BCM’s private Baylor clinic, Harris county hospital’s Smith Clinic and at the Michael E. Debakey VA Medical Center Genetics Clinic. She graduated with honors from NHL Medical College in Gujarat, INDIA after which she pursued a residency in Pathology at the M.P. Shah Cancer Hospital in Gujarat. Subsequently she completed a Masters’ course in Biotechnology at the Stephen F. Austin State University in Nacogdoches, Texas. Following an Internal Medicine residency program at the New York Downtown Hospital in New York, New York she moved to Houston, Texas to start a fellowship in clinical medical genetics and has been faculty at Baylor since 2008.
She has established the adult genetics clinical service at BCM and was instrumental in starting the first known genetics clinic in the VA system in one of the largest VA Medical Centers in the country. Besides her clinical endeavors, she has also been involved in research involving ethical, legal and social implications of large scale genomic risk assessment using the personalized medical genomic profile test available at Baylor’s Medical Genetics Laboratories.
Founder and President
Jonathan Hirsch is the Founder and President of Syapse, a software company transforming healthcare by bringing omics into routine medical use. At Syapse, Jonathan works closely with diagnostic and healthcare providers, helping translate customer problems into software solutions. Jonathan is an Advisory Board member of the SXSW Accelerator, and is a member of the Steering Committee of Free the Data!, an effort started by Genetic Alliance to crowdsource the interpretation of cancer genes. Earlier in his career, Jonathan worked in Neuroscience Commercial Development at Abbott Laboratories, where he developed strategies to fund drug development through partnerships and private equity financing. His research at the Center for Molecular Neurobiology at the University of Chicago helped establish the effect of exercise on promoting hippocampal neurogenesis and combating Alzheimer’s disease. Jonathan received an M.Sci. in Neuroscience from Stanford University, and an A.B. in Biology and Political Philosophy from the University of Chicago.
Professor of Law and Professor, by courtesy, of Genetics
Hank Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He specializes in ethical, legal, and social issues arising from advances in the biosciences, particularly from genetics, neuroscience, and human stem cell research. He directs the Stanford Center for Law and the Biosciences. He chairs the California Advisory Committee on Human Stem Cell Research and serves on the Advisory Council of the National Institute for General Medical Sciences and on the Neuroscience Forum of the Institute of Medicine. From 2007 to 2010 he was a co-director of the Law and Neuroscience Project. In 2006, he was elected a fellow of the American Association for Advancement of Science.
Professor Greely graduated from Stanford in 1974 and from Yale Law School in 1977. He served as a law clerk for Judge John Minor Wisdom on the United States Court of Appeals and for Justice Potter Stewart of the United States Supreme Court. After working during the Carter Administration in the Departments of Defense and Energy, he entered private practice in Los Angeles in 1981 as a litigator with the law firm of Tuttle & Taylor, Inc. He began teaching at Stanford in 1985.
Roger Longman is CEO of Real Endpoints, a start-up company focused on pharmaceutical reimbursement, and aiming to help both payers and product developers improve the value of pharmacotherapy. Its first product assesses – systematically, objectively, and transparently – the value of drugs relative to their competitors.
Until November 2009, Longman was Managing Director, Pharma at Elsevier Business Intelligence, a Reed Elsevier company. He has been involved with the health-care industry for more than 25 years.
In 1983, Longman joined The Wilkerson Group as a writer covering the pharmaceutical and biotech industries for IN VIVO. In 1989, Longman along with David Cassak bought IN VIVO, incorporating it into a new company, Windhover Information, which they built through internal development (with publications such as Start-Up and The RPM Report, several databases, including The Strategic Transactions Database; and a series of senior-executive conferences), and through acquisition.
In 2008, Windhover was acquired by Reed Elsevier and merged with its FDC Reports division (publishers of The Pink Sheet, The Tan Sheet and many other medical-industry newsletters), creating Elsevier Business Intelligence. Longman ran the combined group’s pharmaceutical business until he left to begin working on Real Endpoints.
Editor and Publisher
The Cancer Letter
Paul Goldberg is the editor and publisher of The Cancer Letter, a weekly publication focused on drug development and the politics of cancer. After joining that publication in 1986, he uncovered a key element of a scandal at a genomics research group at Duke University. This led to retraction of papers in the world’s premier medical journals and appointment of a committee of the Institute of Medicine.
Goldberg also broke the story that led to the ImClone scandal and the key stories in the controversy over erythropoiesis-stimulating agents. His reporting on the pharmaceutical and biotechnology industry has triggered numerous investigations by Congressional committees and law enforcement agencies and has been recognized by the Washington DC Professional Chapter of the Society of Professional Journalists, the Gerald Loeb Awards, and the Newsletter and Electronic Publishers Foundation.
His articles have appeared in The New York Times, The Wall Street Journal, The Washington Post and The Washington Monthly, and he has been featured on 60 Minutes, 20/20, CNN and NPR.
His books include “How We Do Harm: A Doctor Break Ranks About Being Sick in America,” with Otis Brawley, (St. Martin’s Press, 2012).
David Martin, Jr.
Chairman and CEO
David Martin, Jr., MD is chairman and CEO of AvidBiotics. Raised in Florida, he attended MIT and received his MD and residency training at Duke. He was a Research Associate at NIH with Gordon Tomkins and moved to UCSF with Tomkins in 1969. At UCSF he became Professor of Medicine and of Biochemistry, while chief of Medical Genetics and an Investigator of the Howard Hughes Medical Institute. In 1982 he joined Genentech as Senior VP of Research and Development, departing Genentech in 1990 to become Executive VP of R&D at the newly formed DuPont Merck Pharmaceutical Co. In 1994 he moved back to San Francisco to become president of Chiron Therapeutics until he became CEO of Lynx. He co-founded Eos Biotechnology in 1997 and AvidBiotics in 2005. He was a Director of Cubist from 1997-2009, Chairman of BayBio in 2007-8 and director of Varian Associates, Inc. and Varian Medical Systems, Palo Alto, from 1994 to 2012.
Avidbiotics, a South San Francisco biotechnology company, engineers complex proteins to target and kill specific bacterial pathogens by a mechanism that is oblivious to antibiotic resistance. While the Company’s strategic pursuit is prophylactic and therapeutic agents for human infections, early applications are in food safety with global partner DuPont.